ClinicalTrials.gg
CompletedNCT05842551Updated Nov 10, 2026

Prismatic Lenses and tDCS in Neglect

An interventional study of Prismatic adaptation and electric stimulation in Stroke, Ischemic, sponsored by Istituti Clinici Scientifici Maugeri SpA. Completed at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.

Enrollment
46th of 50
18 · median 227
Started
2023
with 4 others
No phase
31 of 81
9 open now
Registered
60th of 81
by date

Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 46th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2023, is one of 31 with no phase, and was the 60th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Ischemic Stroke with a site in Italy, or all of them as a file.
02

Study summary

The goal of this study is to to evaluate the effect and feasibility of a rehabilitation protocol with prismatic lenses associated with tDCS, compared to a prismatic lens rehabilitation protocol associated with sham stimulation, in reducing the signs of neglect in a group of patients with spatial heminegligence following ischemic stroke of the right hemisphere.

The secondary objective is to evaluate the impact of this rehabilitation protocol on functional outcome.

03

Conditions studied

  • Stroke, Ischemic

Keywords

  • stroke
  • neglect
  • tDCS
  • prismatic lenses
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >18 years
  • ischemic stroke
  • hospitalization within 90 days of the event

Exclusion criteria

Exclusion Criteria:

  • heamorrhagic stroke
  • history of neurological disease
  • history of psychiatric disease
  • use of alchool and drugs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Experimental

    Patients will receive anodic tEs combined with prismatic lenses for two weeks

    Combination Product: Prismatic adaptation and electric stimulation

  • Sham comparator
    Control

    Patients will receive sham tEs combined with prismatic lenses for two weeks

    Combination Product: Prismatic adaptation and electric stimulation

Interventions

  • Combination productPrismatic adaptation and electric stimulation

    Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group

06

What researchers measure

Primary outcomes

  1. Neuropsychological outcome

    Oxford Cognitive Screening (OCS): is structured in 10 subtests: picture naming (0-4); semantics (0-3); orientation (0-4); visual field (0-4); sentence reading (0-15); number writing (0-3); calculation (0-4); broken hearts (0-50); praxis (0-12); recall and recognition (0-4); trails task (0-13)

    Time frame: Change from baseline OCS at 2 weeks

  2. Neuropsychological outcome

    The semi structured scale for the functional evaluation of extrapersonal neglect (0-9); high score means a worse outcome

    Time frame: Change form baseline the semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks

  3. Neuropsychological outcome

    The semi structured scale for the functional evaluation of personal neglect (0-9); high score means worse outcome

    Time frame: Change form baseline the semi structured scale for the functional evaluation of personal neglect at 2 weeks

  4. Neuropsychological outcome

    Bergegò Scale (0-30); high score means a better outcome

    Time frame: Change from baseline the Bergegò Scale at 2 weeks.

  5. Functional outcome

    Barthel Index (0-100); high score means a better outcome

    Time frame: Change from baseline the Barthel Index at 2 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2026, 37 months.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 37 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2026 → Apr 2026 and completion Dec 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 6, 2023
StartActual
Mar 7, 2023
Primary completionActual
Apr 15, 2026was Jul 2026
CompletionActual
Jul 15, 2026was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Jul 15, 2026→Apr 15, 2026 (actual)
Nov 10, 2026
Study completion
Dec 31, 2026→Jul 15, 2026 (actual)
Nov 10, 2026
Enrollment
30 (estimated)→18 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Jul 15, 2026→Apr 15, 2026 (now actual)
    Study completion Dec 31, 2026→Jul 15, 2026 (now actual)
    Enrollment 30 (estimated)→18 (actual)
    + 5 other changes: verification date, responsible party, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05842551
Collaborators
Azienda USL Toscana Sud Est
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Mar 7, 2023
Primary completion
Apr 15, 2026
Completion
Jul 15, 2026
Last update
Nov 10, 2026

Study contacts

Simona Spaccavento
principal investigator · Istituti Clinici Scientifici Maugeri

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion